Named executive officer

Devdatt (Dev) Kurdikar

President and Chief Executive Officer, Embecta Corp.·Embecta Corp.

About

Mr. Kurdikar is the President and Chief Executive Officer of Embecta. Previously, Mr. Kurdikar was the Worldwide President of Diabetes Care at BD. Prior to that role, Mr. Kurdikar was the President and CEO of Cardiac Science Corporation, a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. Mr. Kurdikar is currently a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Technology Association) and LMG Holdings (a portfolio company of The Riverside Company).

Since 2022
Age 57
Tenure 4 yrs

Also at Embecta Corp.

CA Carrie L. Anderson Director RH Robert (Bob) J. Hombach Director MP Milton M. Morris, Ph.D. Director CM Claire Pomeroy, M.D. Director (Lead Director effective as of the 2026 Annual Meeting) KP Karen N. Prange Director CR Christopher R. Reidy Director

Past roles

No prior roles disclosed
The proxy statement discloses no roles beyond this person's current position. Disclosure is required only for the most recent five years.

Fixed compensation

Data from FY 2025
Salary
$976,923
Component Annual base salary
All other compensation
$23,617
Total compensation
$9,400,088

Performance compensation

Data from FY 2025

Cash incentive

Annual cash incentive
$1,399,540
Form Cash
Evaluation period FY2025

Stock awards

Stock awards
$7,000,008
Form TVUs and PSUs

Related

Source: Embecta Corp. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo